Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study

References

• Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J Clin Med. 2019;8(9). doi:10.3390/jcm8091375
   PubMed Web of Science ®Google Scholar
• de Groot JC, Ten Brinke A, Bel EHD. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1(1):00024–02015. doi:10.1183/23120541.00024-2015
   PubMedGoogle Scholar
• Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160(3):814–830. doi:10.1016/j.chest.2021.04.013
   PubMed Web of Science ®Google Scholar
• Coumou H, Westerhof GA, de Nijs SB, Amelink M, Bel EH. Diagnosing persistent blood eosinophilia in asthma with single blood eosinophil or exhaled nitric oxide level. Respir Med. 2018;141:81–86. doi:10.1016/j.rmed.2018.06.025
   PubMed Web of Science ®Google Scholar
• Matucci A, Maggi E, Vultaggio A. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma. Respir Med. 2019;160:105819. doi:10.1016/j.rmed.2019.105819
   PubMed Web of Science ®Google Scholar
• Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the Pathophysiology of Severe Asthma. Front Physiol. 2019;10:1514. doi:10.3389/fphys.2019.01514
   PubMed Web of Science ®Google Scholar
• Chen M, Shepard K, Yang M, et al. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021;51(4):546–555. doi:10.1111/cea.13790
   PubMed Web of Science ®Google Scholar
• 2023 Gina Main Report. Available from: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf. Accessed March 19, 2024.
   Google Scholar
• European Medicines Agency. Overview of Xolair (omalizumab). EMA/375834/2020. Available from: https://www.ema.europa.eu/en/documents/overview/xolair-epar-medicine-overview_en.pdf. Accessed March 19, 2024.
   Google Scholar
• European Medicines Agency. Cinqaero - Product information. Available from: https://www.ema.europa.eu/en/documents/product-information/cinqaero-epar-product-information_en.pdf. Accessed March 19, 2024.
   Google Scholar
• European Medicines Agency. Nucala - Product Information. Available from: https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf. Accessed March 19, 2024.
   Google Scholar
• European Medicines Agency. Fasenra - Product Information. Available from: https://www.ema.europa.eu/en/documents/product-information/fasenra-epar-product-information_en.pdf. Accessed March 19, 2024.
   Google Scholar
• European Medicines Agency. Dupixent - Product Information. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf. Accessed March 19, 2024.
   Google Scholar
• European Medicines Agency. Tezspire - Product Information. Available from: https://www.ema.europa.eu/en/documents/product-information/tezspire-epar-product-information_en.pdf. Accessed March 19, 2024.
   Google Scholar
• Kayser MZ, Drick N, Milger K, et al. Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months. JAA. 2021;14:863–871. doi:10.2147/JAA.S319572
   Google Scholar
• Maglio A, Vitale C, Pelaia C, et al. Severe asthma remissions induced by biologics targeting IL5/IL5r: results from a multicenter real-life study. IJMS. 2023;24(3):2455. doi:10.3390/ijms24032455
   Google Scholar
• Lanario JW, Cartwright L, Jones RC, Sayers R, Hyland ME, Masoli M. “Life-changing”: the experience of super-responders to biologics in severe asthma. BMC Pulm Med. 2022;22(1):445. doi:10.1186/s12890-022-02241-2
   PubMed Web of Science ®Google Scholar
• Pepper AN, Hanania NA, Humbert M, Casale TB. How to Assess Effectiveness Of Biologics For Asthma And What Steps To Take When There Is Not Benefit. J Allergy Clin Immunol. 2021;9(3):1081–1088. doi:10.1016/j.jaip.2020.10.048
   Web of Science ®Google Scholar
• Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52(4):1800936. doi:10.1183/13993003.00936-2018
   PubMed Web of Science ®Google Scholar
• D’Amato M, Menzella F, Altieri E, et al. Benralizumab in patients with severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: an ANANKE Study post-hoc Analysis. Front Allergy. 2022;3:881218. doi:10.3389/falgy.2022.881218
   PubMedGoogle Scholar
• Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, Phase 3b trial. Lancet Respir Med. 2021;9(3):260–274. doi:10.1016/S2213-2600(20)30414-8
   PubMed Web of Science ®Google Scholar
• Nolasco S, Crimi C, Pelaia C, et al. Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study. J Allergy Clin Immunol. 2021;9(12):4371–4380.e4. doi:10.1016/j.jaip.2021.08.004
   Web of Science ®Google Scholar
• Pavord ID, Deniz Y, Corren J, et al. Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma. J Allergy Clin Immunol. 2022:S2213219822013034. doi:10.1016/j.jaip.2022.11.043
   Web of Science ®Google Scholar
• Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E. Ability of Serum IgE concentration to predict exacerbation risk and benralizumab efficacy for patients with severe eosinophilic asthma. Adv Ther. 2020;37(2):718–729. doi:10.1007/s12325-019-01191-2
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, O’Riordan T, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol. 2020;8(2):516–526. doi:10.1016/j.jaip.2019.08.050
   Web of Science ®Google Scholar
• Pelaia C, Crimi C, Pelaia G, et al. Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clin Exp Allergy. 2020;50(7):780–788. doi:10.1111/cea.13613
   PubMed Web of Science ®Google Scholar
• Corren J, Ambrose CS, Griffiths JM, et al. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: results from the phase 3 NAVIGATOR study. Clin Exper Aller. 2022:cea.14256. doi:10.1111/cea.14256
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Nolasco S, et al. Switch from omalizumab to benralizumab in allergic patients with severe eosinophilic asthma: a real-life experience from Southern Italy. Biomedicines. 2021;9(12):1822. doi:10.3390/biomedicines9121822
   PubMed Web of Science ®Google Scholar
• Menzies-Gow AN, McBrien C, Unni B, et al. Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE Study. JAA. 2022;15:63–78. doi:10.2147/JAA.S328653
   Google Scholar
• Jackson DJ, Burhan H, Menzies-Gow A, et al. Benralizumab effectiveness in severe asthma is independent of previous biologic use. J Allergy Clin Immunol. 2022;10(6):1534–1544.e4. doi:10.1016/j.jaip.2022.02.014
   Web of Science ®Google Scholar
• Numata T, Araya J, Miyagawa H, et al. Effectiveness of switching biologics for severe asthma patients in Japan: a single-center retrospective study. JAA. 2021;14:609–618. doi:10.2147/JAA.S311975
   Google Scholar
• Dagher R, Kumar V, Copenhaver AM, et al. Novel mechanisms of action contributing to benralizumab’s potent anti-eosinophilic activity. Eur Respir J. 2022;59(3):2004306. doi:10.1183/13993003.04306-2020
   PubMed Web of Science ®Google Scholar
• Bergantini L, d’Alessandro M, Pianigiani T, Cekorja B, Bargagli E, Cameli P. Benralizumab affects NK cell maturation and proliferation in severe asthmatic patients. Clin Immunol. 2023;253:109680. doi:10.1016/j.clim.2023.109680
   PubMed Web of Science ®Google Scholar
• Characterisation of Italian severe uncontrolled asthmatic patieNts key features when receiving benralizumab (ANANKE). Available from: https://clinicaltrials.gov/ct2/show/NCT04272463. Accessed March 19, 2024.
   Google Scholar
• Menzella F, Bargagli E, Aliani M, et al. Characterization of Italian severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study. Respir Res. 2022;23(1):36. doi:10.1186/s12931-022-01952-8
   PubMed Web of Science ®Google Scholar
• Caruso C, Cameli P, Altieri E, et al. Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: an ANANKE study post hoc analysis. Front Med. 2022;9:950883. doi:10.3389/fmed.2022.950883
   Web of Science ®Google Scholar
• Vultaggio A, Aliani M, Altieri E, et al. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study. Respir Res. 2023;24(1):135. doi:10.1186/s12931-023-02439-w
   PubMed Web of Science ®Google Scholar
• Reimbursement decree for human use of Dupixent - Italian Medicines Agency. Available from: https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2020-12-09&atto.codiceRedazionale=20A06599&elenco30giorni=true. Accessed March 19, 2024.
   Google Scholar
• Kavanagh JE, d’Ancona G, Elstad M, et al. Real-world effectiveness and the characteristics of a “super-responder” to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491–500. doi:10.1016/j.chest.2020.03.042
   PubMed Web of Science ®Google Scholar
• Seccia V, D’Amato M, Scioscia G, et al. Management of patients with severe asthma and chronic rhinosinusitis with nasal polyps: a multidisciplinary shared approach. JPM. 2022;12(7):1096. doi:10.3390/jpm12071096
   Google Scholar
• Caminati M, Marcon A, Guarnieri G, et al. Benralizumab efficacy in late non-responders to mepolizumab and variables associated with occurrence of switching: a real-word perspective. JCM. 2023;12(5):1836. doi:10.3390/jcm12051836
   Google Scholar
• Kraft M, Brusselle G, FitzGerald JM, et al. Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. Eur Respir J. 2021;58(6):2100413. doi:10.1183/13993003.00413-2021
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Dalal AA, et al. Blood eosinophil count and outcomes in severe uncontrolled asthma: a prospective study. J Allergy Clin Immunol. 2017;5(1):144–153.e8. doi:10.1016/j.jaip.2016.07.015
   Web of Science ®Google Scholar
• Gómez-Bastero Fernández A, Medina Gallardo JF, Delgado Romero J, et al. Effectiveness of switching to benralizumab in severe refractory eosinophilic asthma. JAA. 2022;15:727–735. doi:10.2147/JAA.S358705
   Google Scholar
• Kavanagh JE, Hearn AP, d’Ancona G, et al. Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma. Allergy. 2021;76(6):1890–1893. doi:10.1111/all.14693
   PubMed Web of Science ®Google Scholar
• Soremekun S, Heaney LG, Skinner D, et al. Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study. Thorax. 2022:217032. doi:10.1136/thorax-2021-217032
   Web of Science ®Google Scholar
• Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J. 2014;44(1):239–241. doi:10.1183/09031936.00220413
   PubMed Web of Science ®Google Scholar
• Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med. 2000;161(1):64–72. doi:10.1164/ajrccm.161.1.9809100
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–1096.e5. doi:10.1016/j.jaci.2013.05.020
   PubMed Web of Science ®Google Scholar
• Poznanski SM, Mukherjee M, Zhao N, et al. Asthma exacerbations on benralizumab are largely non‐eosinophilic. Allergy. 2021;76(1):375–379. doi:10.1111/all.14514
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10(1):47–58. doi:10.1016/S2213-2600(21)00352-0
   PubMed Web of Science ®Google Scholar
• Chan JSK, Murray RB, Price D. Oral corticosteroids in asthma and beyond: moving forward. Eur Respir J. 2022;60(3):2200776. doi:10.1183/13993003.00776-2022
   PubMed Web of Science ®Google Scholar
• Gurnell M, Heaney LG, Price D, Menzies‐Gow A. Long‐term corticosteroid use, adrenal insufficiency and the need for steroid‐sparing treatment in adult severe asthma. J Intern Med. 2021;290(2):240–256. doi:10.1111/joim.13273
   PubMed Web of Science ®Google Scholar
• Li H, Zhang Q, Wang J, et al. Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: a 5-year retrospective study from a single tertiary hospital. World Allergy Organ J. 2021;14(9):100547. doi:10.1016/j.waojou.2021.100547
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti–interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199–204. doi:10.1164/rccm.200208-789OC
   PubMed Web of Science ®Google Scholar
• McDowell PJ, Diver S, Yang F, et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respir Med. 2021;9(10):1174–1184. doi:10.1016/S2213-2600(21)00004-7
   PubMed Web of Science ®Google Scholar